Novo Nordisk Heads to London With a New Name, a $1.4 Billion Bet and Plenty to Prove
Published on 09/20/2026 at 21:02 | Editorial boerse-global.de
When Mike Doustdar takes the stage in London on Monday, he will do so as the chief executive of a company that is quietly becoming something else. Novo Nordisk A/S keeps its legal name, but day-to-day the Danish drugmaker now goes by "Novo" — a cosmetic shift, perhaps, yet one that arrives alongside a rewritten corporate playbook dubbed "The Novo Way," built around customer focus, competitiveness, clarity and integrity.
The rebrand is the softer edge of a much harder message. Doustdar rallied staff last Tuesday to sharpen the company's commercial instincts and recover momentum in obesity care, and Monday's capital markets day — set for 21 September — is his first full presentation of where Novo intends to go next.
A stock under pressure, a pipeline under scrutiny
Investors have reasons to want answers. The shares finished Friday at EUR 37.58, leaving a market value of EUR 161.40 billion and a year-to-date decline of 15%. Morgan Stanley, which cut the stock to "Underweight" from "Equal-Weight" on 11 September while holding its USD 40.00 price target, pointed to softer medium-term growth and patent exposures that begin to bite after 2030.
The central question in London is diversification. Diabetes and obesity account for more than 90% of group revenue, and Morgan Stanley estimates semaglutide alone will drive roughly 75% of sales this year. Citi, meanwhile, sees US rival Eli Lilly stretching its lead in prescriptions — a gap that has major shareholders pressing for action. Flossbach von Storch, the Cologne-based asset manager, has been pushing for more bolt-on acquisitions and strategic partnerships to refresh the clinical pipeline.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Deals, approvals — and setbacks
Some of that is already happening. On Thursday Novo signed a licensing and development agreement with Orbis Medicines covering oral cardiometabolic therapies, a pact worth up to USD 1.4 billion that also gives the Danish group an equity stake in the privately held partner. The company has also picked up obesity development programs from a US biotech.
European regulators handed over two pieces of good news. On Friday the CHMP recommended approval of Sogroya (somapacitan), a once-weekly therapy for children with idiopathic short stature, with a final European Commission decision expected during 2026. The same committee backed a hemophilia treatment.
Not everything has gone Novo's way. According to Reuters, the company halted two trials of ziltivekimab in heart failure on 7 September after an independent data monitoring committee concluded that a divergent result from an earlier failed late-stage study was unlikely. A separate post-heart-attack trial continues, with data expected in the first half of 2027.
Manufacturing cuts and US litigation
Alongside the strategic reset, management is trimming operations. The Bloomington, Indiana plant, where Wegovy and Ozempic are among the products manufactured, is being scaled back. Legal risk is building too: more than 90 lawsuits have been filed in New Jersey alleging that the drugs caused the eye condition NAION. Europe's EMA has classified semaglutide as a very rare cause of the vascular occlusion, while the FDA has been reviewing the matter since late 2024 without imposing a warning requirement.
The numbers investors will weigh
For the full year, Novo is targeting revenue and operating profit growth of between zero and minus six percent. Second-quarter revenue came in at DKK 78.49 billion, with operating profit of DKK 33.39 billion. Hard figures for the third quarter are due on 4 November — but until then, the guidance Doustdar sketches on Monday is likely to set the tone for how the market judges Novo's chances of a turnaround.
Ad
Novo Nordisk Stock: New Analysis - 20 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
